Ignaty Leshchiner, PhD

Assistant Professor, Boston University Chobanian & Avedisian School of Medicine

Biography

Dr. Leshchiner is interested in applying new genomic technologies such as blood biopsy, long-range read phasing, and single cell sequencing for analysis and understanding of biology behind tumor development, treatment evasion, and progression to metastasis. His background is in developing statistical methods for analysis of genomics data and application of these methods to understanding biology and finding treatment for various disease conditions.

Prior to joining Boston University, Dr. Leshchiner served as the associate director of the Computation Biology and Cancer Resistance Department of the Broad Institute of MIT and Harvard. He remains a member of the institute's affiliated faculty. Leshchiner also worked for Partners Healthcare as a bioinformatician in the genetics division of Brigham and Women’s Hospital, where he contributed to the CLARITY Challenge-winning team in 2012. He has previous consulting experience for Hybrid Silica Technologies and prior research fellowships at UMass Lowell and Moscow State University.

Dr. Leshchiner obtained a Ph.D. in chemistry from Moscow State University, which included a visiting scientist appointment in the Langer Lab at MIT. He completed postdoctoral training in bioinformatics and computational biology at Harvard Medical School.

Publications

  • Published 6/4/2026

    Keegan J, Sorbello S, Mori J, Muratani S, Leshchiner I, Heaphy CM, Flynn RL. Complex structural variations functionally inactivate the telomerase chaperone TCAB1 in osteosarcoma. BMC Cancer. 2026 Jun 04; 26(1). PMID: 42243724.

    Read at: PubMed

  • Published 4/27/2026

    Leal AA, Tafrate S, He X, Bryant DL, Herring MB, Andrade M, McWhirter JB, Quiñones-Molina AA, Gummuluru S, Sagar M, Flynn RL, Leshchiner I, Henderson AJ. Bloom syndrome helicase is required for efficient HIV-1 reverse transcription in macrophages. bioRxiv. 2026 Apr 27. PMID: 42094387.

    Read at: PubMed

  • Published 1/2/2026

    Keegan J, Sorbello S, Mori J, Muratani S, Leshchiner I, Heaphy CM, Flynn RL. Functional inactivation of the telomerase chaperone TCAB1 primes cells for the activation of ALT in osteosarcoma. bioRxiv. 2026 Jan 02. PMID: 41509329.

    Read at: PubMed

  • Published 8/22/2025

    Kübler K, Nardone A, Anand S, Gurevich D, Gao J, Droog M, Hermida-Prado F, Akhshi T, Feiglin A, Feit AS, Cohen Feit G, Dackus G, Pun M, Kuang Y, Cha J, Miller M, Gregoricchio S, Lanfermeijer M, Cornelissen S, Gibson WJ, Paweletz CP, Van Allen EM, van Leeuwen FE, Nederlof PM, Nguyen QD, Mourits MJE, Radovich M, Leshchiner I, Stewart C, Matulonis UA, Zwart W, Maruvka YE, Getz G, Jeselsohn R. Tamoxifen induces PI3K activation in uterine cancer. Nat Genet. 2025 Sep; 57(9):2192-2202. PMID: 40846762.

    Read at: PubMed

  • Published 2/5/2025

    Braun DA, Moranzoni G, Chea V, McGregor BA, Blass E, Tu CR, Vanasse AP, Forman C, Forman J, Afeyan AB, Schindler NR, Liu Y, Li S, Southard J, Chang SL, Hirsch MS, LeBoeuf NR, Olive O, Mehndiratta A, Greenslade H, Shetty K, Klaeger S, Sarkizova S, Pedersen CB, Mossanen M, Carulli I, Tarren A, Duke-Cohan J, Howard AA, Iorgulescu JB, Shim B, Simon JM, Signoretti S, Aster JC, Elagina L, Carr SA, Leshchiner I, Getz G, Gabriel S, Hacohen N, Olsen LR, Oliveira G, Neuberg DS, Livak KJ, Shukla SA, Fritsch EF, Wu CJ, Keskin DB, Ott PA, Choueiri TK. A neoantigen vaccine generates antitumour immunity in renal cell carcinoma. Nature. 2025 Mar; 639(8054):474-482. PMID: 39910301.

    Read at: PubMed

View All 66 Publications:   View Full Profile in BUMC

Other Positions

  • Graduate Medical Sciences Educator and Mentor (Primary Mentor of Graduate Students)
    Boston University Chobanian & Avedisian School of Medicine, Graduate Medical Sciences

Websites

Education

  • Moscow State University, PhD
  • Moscow State University, MS

View all profiles